Florida is currently home to 3730 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CERAMENT™| Bone Void Filler Device Registry
Recruiting
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Golden Orthopedic Knee, Hip, Shoulder and Foot Center, Boca Raton, Florida
Conditions: Orthopedic Disorder
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Recruiting
This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/25/2024
Locations: Orlando Health, Orlando, Florida
Conditions: Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor, Bile Duct Diseases, Bile Duct Cancer, Lymph Node Disease, Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Cancer
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
Recruiting
To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/22/2024
Locations: Site, Delray Beach, Florida
Conditions: Demodex Blepharitis
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
Recruiting
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Hi Tech and Global Research, Coral Gables, Florida
Conditions: NASH, Cirrhosis, Liver
Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)
Recruiting
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
Gender:
ALL
Ages:
All
Trial Updated:
03/20/2024
Locations: Encore Borland-Groover, Jacksonville, Florida
Conditions: Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
Recruiting
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Maitland, Florida
Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers
Recruiting
The goal of this project evaluate the efficacy of NiteCAPP in improving insomnia in a rural dementia caregiver sample (n of 100 caregiver and PWD dyads). We will measure both the short term (post-treatment) and long term (6 and 12 months) effects of the intervention on CG sleep, arousal, inflammation, health, mood, burden and cognitive function, and PWD sleep.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Insomnia, Dementia
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of Miami, Coral Gables, Florida
Conditions: COVID-19
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Jacksonville, Florida
Conditions: Neoplasms
Reducing Wound Infections Using Bioelectric Wound Dressings
Recruiting
The purpose of this study is to compare the outcomes of using Bioelectric wound dressing on the pre-operative wound site and post operatively and compared it outcomes to the standard of care chlorhexidine skin preparation.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/13/2024
Locations: AdventHealth Celebration, Kissimmee, Florida
Conditions: Surgical Site Infection
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Recruiting
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: St. Anthony's Hospital - BayCare Health System, Saint Petersburg, Florida
Conditions: Non Small Cell Lung Cancer